Innate Pharma SA (OTCMKTS:IPHYF – Get Free Report) was the target of a large increase in short interest in the month of June. As of June 15th, there was short interest totaling 4,661 shares, an increase of 9,222.0% from the May 31st total of 50 shares. Based on an average trading volume of 0 shares, the short-interest ratio is presently ∞ days. Approximately 0.0% of the shares of the company are short sold.
Innate Pharma Stock Performance
Shares of OTCMKTS:IPHYF opened at $1.65 on Friday. The company’s 50-day moving average price is $1.70 and its 200 day moving average price is $1.89. Innate Pharma has a fifty-two week low of $1.37 and a fifty-two week high of $2.25.
About Innate Pharma
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.
The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.
Recommended Stories
- Five stocks we like better than Innate Pharma
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
